Overview
CARB-X is a global non-profit partnership that accelerates the development of antibacterial products to combat drug-resistant bacteria. The organization provides non-dilutive funding, scientific expertise, regulatory guidance, and business support to developers of new antibiotics, preventatives, rapid diagnostics, and related products. CARB-X maintains the world's most scientifically diverse early-stage pipeline, supporting projects from basic research through Phase 1 clinical trials and prototype development.
Frequently asked questions
- What types of antibacterial products does CARB-X support?
- CARB-X supports the development of new antibiotics, preventatives, rapid diagnostics, and other products to prevent, diagnose, and treat life-threatening bacterial infections caused by drug-resistant bacteria. The organization supports therapeutics and preventatives from early development stages through Phase 1 clinical trials, and diagnostics from feasibility through prototype development.
- What support does CARB-X provide beyond funding?
- Beyond non-dilutive funding, CARB-X provides comprehensive support including scientific expertise, regulatory guidance, and business advisory services. The organization connects developers with expert advisors, subject matter experts across multiple disciplines, and facilitates market-shaping support to ensure products reach target markets, including low- and middle-income countries.
- What is CARB-X's focus in terms of bacterial targets?
- CARB-X focuses on the most serious drug-resistant bacteria and syndromes with the highest degrees of mortality and morbidity globally. Recent funding priorities include novel chemistry approaches against known antimicrobial resistance targets to unlock innovative starting points for therapeutics addressing dangerous drug-resistant bacterial infections.
- How does CARB-X support early-stage research?
- CARB-X created Portfolio Acceleration Tools to help developers improve predictive models and compare compound toxicity. The organization publishes its methodologies so researchers worldwide can use them in different laboratories to demonstrate proof-of-concept for new antibacterial candidates.